OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
August 01, 2018
CMOs have been active over the past year in expanding their biologics production and capabilities.
This article provides a sampling of the latest investments, expansions, and acquisitions by small-molecule contract service providers.
Heightened uncertainty means CDMO executives need to play out planning scenarios.
Why shouldn’t biopharmaceutical manufacturers be able to leverage standardized construction practices to improve time to market?
Real-life examples illustrate how to reduce the risks for each transferring partner and ensure that the development process meets regulatory requirements.
July 27, 2018
Quartzy, an online laboratory supply management company, will offer lab products from Bioline, Biotium, and MP Biomedicals.
July 24, 2018
The API and drug product provider will invest £375,000 (US$493,000) in additional nuclear magnetic resonance (NMR) instrumentation at its headquarters in Craigavon, UK.
The glass and chemical provider will expand its synthetic pharmaceutical intermediate and API production capacity at its plant in Chiba, Japan.
July 23, 2018
The acquisition will place Cambrex into the finished dosage form CDMO market.
July 18, 2018
CELLforCURE will produce cancer CAR-T treatments for Novartis at a manufacturing facility in Les Ulis (Essonne), France.